BioVaxys Technology Corp. (CSE:BIOV)

Canada flag Canada · Delayed Price · Currency is CAD
0.0800
0.00 (0.00%)
At close: Mar 20, 2026
Market Cap3.53M -77.5%
Revenue (ttm)n/a
Net Income-5.97M
EPS-0.22
Shares Out44.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume29,049
Average Volume137,613
Open0.0800
Previous Close0.0800
Day's Range0.0800 - 0.0800
52-Week Range0.0750 - 0.5500
Beta0.71
RSI29.25
Earnings DateMar 3, 2026

About BioVaxys Technology

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer... [Read more]

Industry Biotechnology
Sector Healthcare
CEO James Passin
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements